Adalvo and Cipla are pleased to announce the expansion of their strategic partnership with the launch of Vyfocis® capsules in South Africa.
The launch represents a significant step in both companies' commitment to the South African market, and reflects their shared focus on bringing high-quality, affordable medicines to the region.
Anil Okay, CEO of Adalvo, commented: "South Africa represents an important market for Adalvo, and we are proud to be entering it alongside Cipla — a partner whose commitment to healthcare access across the African continent matches our own."
Vyfocis® addresses a recognised clinical need in South Africa and supports prescribers and patients by expanding access to treatments that meet the highest international quality standards.
Cipla South Africa is a cornerstone of Cipla's presence across more than 80 countries, with a long-standing commitment to making medicines available to those who need them. This launch aligns with Cipla's Caring for Life philosophy and reinforces its role in advancing healthcare across the region.